Pediatrix Medical Group (FRA:PDC) EBIT: €225 Mil (TTM As of Mar. 2026)


FRA:PDC Pediatrix Medical Group Inc FRA:PDC
63 GF Score
Price €20.40
GF Value €11.23
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Pediatrix Medical Group EBIT?

Pediatrix Medical Group FRA:PDC -0.97% 63 EBIT is €225 Mil as of Mar. 2026. GuruFocus rates FRA:PDC with a GF Score™ of 63/100 and a GF Value™ of €11.23 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Pediatrix Medical Group's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was €41 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was €225 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pediatrix Medical Group's annualized ROC % for the quarter that ended in Mar. 2026 was 9.00%. Pediatrix Medical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 315.64%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Pediatrix Medical Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 11.38%.


Pediatrix Medical Group  (FRA:PDC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pediatrix Medical Group's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=161.164 * ( 1 - 23.87% )/( (1266.637 + 1459.746)/ 2 )
=122.6941532/1363.1915
=9.00 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1918.678 - 358.279 - ( 426.763 - max(0, 358.279 - 652.041+426.763))
=1266.637

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1790.805 - 206.157 - ( 284.563 - max(0, 382.882 - 507.784+284.563))
=1459.746

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Pediatrix Medical Group's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=162.996/( ( (29.318 + max(-100.21, 0)) + (67.44 + max(6.522, 0)) )/ 2 )
=162.996/( ( 29.318 + 73.962 )/ 2 )
=162.996/51.64
=315.64 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(196.134 + 0 + 29.144) - (358.279 + 0 + -32.791)
=-100.21

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(194.453 + 0 + 18.226) - (206.157 + 0 + 0)
=6.522

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Pediatrix Medical Group's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=225.13/1978.008
=11.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pediatrix Medical Group EBIT Related Terms


Pediatrix Medical Group EBIT Historical Data

* Premium members only.

The historical data trend for Pediatrix Medical Group's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pediatrix Medical Group EBIT Chart

Pediatrix Medical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 180.50 114.29 -5.76 -57.87 215.55

Pediatrix Medical Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.45 55.57 82.41 46.40 40.75

FRA:PDC vs SGRY, ADUS, SNDA: EBIT Comparison

For the Medical Care Facilities subindustry, Pediatrix Medical Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pediatrix Medical Group EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Pediatrix Medical Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pediatrix Medical Group's EV-to-EBIT falls into.


FRA:PDC
63GF Score
Pediatrix Medical Group Inc FRA:PDC
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pediatrix Medical Group EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €225 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of €225 Mil mean?
Pediatrix Medical Group (FRA:PDC) has a EBIT of €225 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pediatrix Medical Group.
Is Pediatrix Medical Group's EBIT too high?
Pediatrix Medical Group's current EBIT is €225 Mil. Overall, Pediatrix Medical Group has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pediatrix Medical Group's EBIT compare to SGRY and ADUS?
Pediatrix Medical Group's EBIT of €225 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Pediatrix Medical Group. Pediatrix Medical Group's current EBIT is €225 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pediatrix Medical Group stock overvalued right now?
Based on GuruFocus' analysis, Pediatrix Medical Group (FRA:PDC) is currently considered Significantly Overvalued. The stock's GF Value™ is €11.23, compared to a current price of €20.40 — trading 81.7% above its estimated fair value. The current EBIT is €225 Mil. Pediatrix Medical Group's overall GF Score™ is 63/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Pediatrix Medical Group (FRA:PDC), the current EBIT is €225 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pediatrix Medical Group (FRA:PDC) Overvalued in 2026?

Based on GuruFocus' analysis, Pediatrix Medical Group stock appears to be overvalued. The current stock price of €20.40 is trading 81.7% above its estimated GF Value™ of €11.23. GuruFocus considers Pediatrix Medical Group to be Significantly Overvalued.

Key valuation signals for FRA:PDC:

  • EBIT: €225 Mil
  • GF Value™: €11.23 vs. price of €20.40 (81.7% above fair value)
  • GF Score™: 63/100 with 7 warning signs

No single metric tells the full story. See the FRA:PDC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pediatrix Medical Group Business Description

Other Exchanges MD:USA
Address 1301 Concord Terrace, Sunrise, FL, USA, 33323
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
63GF Score

Get the complete analysis for FRA:PDC

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.40
Price
€11.23
GF Value